Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland

Clinical Genetics

Volumn 88, Issue 4, 2015, Pages 366-370

  Cybulski, C ^a   Lubinski J ^a   Wokolorczyk D ^a   Kuzniak W ^a   Kashyap, A ^a   Sopik, V ^b   Huzarski, T ^a   Gronwald, J ^a   Byrski, T ^a   Szwiec, M ^c   Jakubowska, A ^a   Gorski B ^a   Debniak, T ^a   Narod, S A ^b   Akbari, M R ^b  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF TORONTO   (Canada)

^c Tadeusz Koszarowski Regional Oncology Center   (Poland)

Author keywords

ATM; BRCA1; BRCA2; Breast cancer; BRIP; CHEK2; Hereditary; Mutation; PALB2; Whole exome sequencing

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; EXOME; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; POLAND; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; BREAST TUMOR; DNA MUTATIONAL ANALYSIS; FOUNDER EFFECT; GENETIC SCREENING; GENETICS;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; CHECKPOINT KINASE 2; CHEK2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHECKPOINT KINASE 2; DNA MUTATIONAL ANALYSIS; FEMALE; FOUNDER EFFECT; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NUCLEAR PROTEINS; POLAND; TUMOR SUPPRESSOR PROTEINS;

EID: 84941640729     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12524     Document Type: Article

References (32)

1. Gonzalez KD, Noltner KA, Buzin CH et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009: 27: 1250-1256.
2. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012: 18: 400-407.
3. Rahman N, Seal S, Thompson D et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007: 39: 165-167.
4. Bogdanova N, Feshchenko S, Schürmann P et al. Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer 2008: 122: 802-806.
5. De Brakeleer S, De Grève J, Loris R et al. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. Hum Mutat 2010: 31: E1175-E1185.
6. Meijers-Heijboer H, van den Ouweland A, Klijn J et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002: 31: 55-59.
7. Park DJ, Lesueur F, Nguyen-Dumont T et al. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012: 90: 734-739.
8. Prokofyeva D, Bogdanova N, Dubrowinskaja N et al. Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom's syndrome, is associated with breast cancer in Slavic populations. Breast Cancer Res Treat 2013: 137: 533-539.
9. Seal S, Thompson D, Renwick A et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006: 38: 1239-1241.
10. Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006: 38: 873-875.
11. Chong HK, Wang T, Lu HM et al. The validation and clinical implementation of BRCA plus: a comprehensive high-risk breast cancer diagnostic assay. PLoS One 2014: 9: e97408.
12. Kurian AW, Hare EE, Mills MA et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014: 32: 2001-2009.
13. Laduca H, Laduca H, Stuenkel AJ, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2, 000 patients. Genet Med 2014, doi:10.1038/gim.2014.40
14. Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2014, 10.1002/cncr29010
15. Szwiec M, Jakubowska A, Górski B, et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. Clin Genet 2014. 10.1111/cge.12360.
16. Cybulski C, Wokołorczyk D, Huzarski T et al. A deletion in CHEK2 of 5, 395bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 2007: 102: 119-122.
17. Steffen J, Nowakowska D, Niwińska A et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer 2006: 119: 472-475.
18. Brozek I, Cybulska C, Ratajska M et al. Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet 2011: 52: 325-330.
19. Gorski B, Debniak T, Masojć B et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer 2003: 106: 379-381.
20. Vahteristo P, Bartkova J, Eerola H et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002: 71: 432-438.
21. Gorski B, Cybulski C, Huzarski T et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 2005: 92: 19-24.
22. Wetterstrand, K. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP), from: http://www.genome.gov/sequencingcosts. Accessed on July 15, 2014.
23. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009: 25: 1754-1760.
24. Picard, from http://picard.sourceforge.net. Accessed on July 15, 2014.
25. McKenna A, Hanna M, Banks E et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010: 20: 1297-1303.
26. Casadei S, Norquist BM, Walsh T et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011: 71: 2222-2229.
27. Noskowicz M, Bogdanova N, Bermisheva M et al. Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe. Fam Cancer 2014: 13: 137-142.
28. Dansonka-Mieszkowska A, Kluska A, Moes J et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet 2010: 11: 20.
29. Janatova M, Kleibl Z, Stribrna J et al. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidemiol Biomarkers Prev 2013: 22: 2323-2332.
30. Antoniou AC, Casadei S, Heikkinen T et al. Breast cancer risks in families with mutations in PALB2. N Engl J Med 2014: 7: 497-506.
31. Tavtigian SV, Oefner PJ, Babikyan D et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009: 85: 427-446.
32. Ratajska M, Antoszewska E, Piskorz A et al. Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res Treat 2012: 131: 89-97.